PTC Therapeutics issues $550M zero-coupon convertible notes, refinances 2026 debt

Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read

Key Changes

• high

  Issued $550M in 0% convertible senior notes due 2031, convertible at $107.48/share (9.3042 shares per $1,000 principal), representing potential dilution of ~5.1M shares if fully converted.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  Used $328.8M of proceeds to repurchase $222M principal of existing 1.50% convertible notes due 2026, reducing outstanding balance to $55.5M and extending debt maturity while eliminating interest expense.

  Item 8.01 — Other Events verify on EDGAR →
• medium

  Notes are redeemable after June 2029 only if stock trades above $139.72 (130% of conversion price) for 20 of 30 trading days; holders can convert under specific conditions before March 2031.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →